Phase II prospective trial of cetuximab and radiotherapy for locally advanced, squamous cell carcinomas of the head and neck in patients >70 years old or with comorbidities not-eligible for platinum-based chemotherapy.

Authors:

Abstract
6071 Background: We designed a single arm phase II trial to determine the efficacy and toxicity of concurrent cetuximab (C) radiotherapy (RT) in patients non-eligible for standard chemotherapy. Non-eligibility was defined as age > 70 years (yrs), co-morbidities that preclude platinum-based chemotherapy, or creatinine clearance (CrCl) < 30 mL/min. Primary endpoint was progression free survival. Methods: 22 stage III/IVA patients (pts) were enrolled. The median age was 70 years (range: 40-85), 50% had eGFR with < 90 mL/min, 64% were males, 36% were females; 64% Caucasian, 36 % had an ECOG performance status (PS) of 0, 64% ECOG PS of 1. All pts received C 400 mg/m2 day (d) 0, then 250 mg/m2 d 7 and weekly during RT. Pts were treated with a planned 70 Gray (Gy) in 35 fractions over 7 weeks to the gross tumor and 50-60 Gy to subclinical target volumes.Results: As of January 2016 with a median follow up of 22.8 months and 22 evaluable pts, the median PFS was 30.07 months (95% CI: 2.93, > 50). The overall survival was 33.8 months (95% CI: 9.2, > 50). 6 pts (27%) have recurred, all of whom have died. Treatment related grade 3 toxicities were seen in 7 pts (32%), no grade 4 toxicities were seen. The most common grade 3 toxicities were mucositis (5 pts), dysphagia (4 pts), and dermatitis (3 pts). Conclusions: The results of this phase II prospective study suggest that in patients > 70 yrs old or with comorbidities, precluding platinum-based chemotherapy, tolerate treatment with C+RT well, though survival rates are lesser when compared with historical controls. Clinical trial information: NCT00904345.